Challenging Biological Pacemaker Dogma: The Role of Hcn2

Research published June 11, 2026, indicates that the transcription factor TBX18 is not the primary driver for creating biological pacemakers, contradicting long-held scientific assumptions. According to Medical Xpress, the Hcn2 ion channel is more effective at inducing the electrical activity required to regulate heartbeats, offering a more viable path toward replacing electronic pacemaker implants.

Biological pacemakers aim to reprogram ordinary heart muscle cells into specialized pacemaker cells that can trigger spontaneous electrical impulses. This process would eliminate the need for surgical implantation of battery-powered devices, which are prone to lead failure and infection, according to the report from Medical Xpress.

Why did TBX18 fail as a pacemaker driver?

For years, researchers focused on TBX18, a transcription factor, believing it acted as a master switch capable of converting cardiomyocytes into sinoatrial node-like cells. The prevailing theory suggested that TBX18 could rewrite the genetic identity of a heart cell to make it inherently rhythmic, according to Medical Xpress.

Recent findings challenge this dogma by demonstrating that TBX18 often fails to produce consistent, reliable pacing on its own. The research indicates that while TBX18 might alter some cellular characteristics, it does not consistently establish the necessary electrical current to maintain a steady heart rate in living subjects, Medical Xpress reports.

How does Hcn2 deliver pacing results?

The Hcn2 channel functions differently than TBX18 because it is an ion channel rather than a genetic switch. It is responsible for the “funny current,” a specific type of electrical leak that allows pacemaker cells to spontaneously depolarize and trigger a heartbeat, according to the Medical Xpress report.

By directly expressing Hcn2 in non-pacemaker heart cells, researchers found they could successfully induce the rhythmic firing necessary for heart regulation. This approach bypasses the complex genetic reprogramming attempted with TBX18 and instead focuses on the immediate electrical mechanism that drives the heart’s natural pacemaker, the sinoatrial node.

How do TBX18 and Hcn2 compare in biological pacing?

The distinction between the two methods centers on the difference between cellular identity and cellular function. TBX18 attempts to change what the cell is, while Hcn2 changes what the cell does.

• TBX18: A transcription factor designed to reprogram the cell’s genetic expression to mimic a pacemaker cell. Medical Xpress notes this method has been inconsistent in delivering functional pacing.
• Hcn2: A hyperpolarization-activated cyclic nucleotide-gated channel that directly creates the electrical current needed for pacing. This method has proven more effective at delivering the required electrical output.

This shift in focus suggests that the electrical properties of the cell are more critical for successful biological pacing than the overall genetic identity of the cell, according to the findings reported by Medical Xpress.

What happens next for biological pacemaker research?

The discovery that Hcn2 is a more reliable driver shifts the trajectory of gene therapy for cardiac arrhythmias. Researchers must now determine the most effective way to deliver Hcn2 to the heart, likely using viral vectors or other gene-delivery systems, according to the Medical Xpress report.

One remaining challenge is ensuring that Hcn2-induced pacing remains stable over long periods and responds correctly to the body’s needs, such as increasing the heart rate during exercise. Medical Xpress indicates that while Hcn2 delivers the necessary current, the precision of this biological control must be refined before it can enter human clinical trials.

Current electronic pacemakers remain the standard of care, but the success of Hcn2 provides a concrete biological alternative that could eventually reduce the long-term complications associated with hardware implants, according to the report.